Eli Lilly and Company is looking to expand their product line by acquiring a smaller company. This engagement looks into the public, legal, and financial statements of Sorrento Therapeutics. We are limited as we only have access to what Sorrento Therapeutics has released to the public. The major steps involved with this engagement consisted of doing our due diligence to research the company. This included looking into the values and ethics of the company and making sure that they were a good fit for Eli Lilly. Another part of our due diligence was to make sure that Sorrento Therapeutics had no outstanding legal issues. The final step of our due diligence was to make sure Sorrento Therapeutics was not in debt or financially plummeting.
